GlycoMimetics Announces National Cancer Institute Phase 2/3 Study of Uproleselan Did Not Meet Primary Endpoint

Stock Information for Augmedix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Augmedix Inc.

Kuehn Law Encourages PFIE, GLYC, RVNC, and RCM Investors to Contact Law Firm
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE, CPTN, GLYC, ARC on Behalf of Shareholders
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating GlycoMimetics, Inc. Merger
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Profire Energy, Inc. (Nasdaq - PFIE), Cepton, Inc. (Nasdaq - CPTN), GlycoMimetics, Inc. (Nasdaq - GLYC), ARC Document Solutions, Inc. (NYSE - ARC)
Shareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders
GLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to Shareholders
GlycoMimetics Enters Into Acquisition Agreement With Crescent Biopharma

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.